Literature DB >> 907991

Statistical methods for studying multiple primary malignant neoplasms.

B S Schoenberg, M H Myers.   

Abstract

Case reports and case series dealing with multiple primary malignant neoplasms provided useful criteria for defining and documenting this phenomenon. The formation of tumor registries greatly aided in identifying a sufficient number of multiple primary cancer patients and facilitated case-control comparisons. Reports of two or more neoplasms occurring together in the same individual do not constitute proof of a significant association; the tumors must be shown to occur together more frequently than expected by chance. The person-years approach applied to data derived from a well-defined population makes it possible to compare the observed and expected number of subsequent primary cancers. The results of the most sophisticated procedures are no better than the quality of the data, however, and one must critically examine possible sources of bias before accepting statistical significance as representing biologic significance.

Entities:  

Mesh:

Year:  1977        PMID: 907991     DOI: 10.1002/1097-0142(197710)40:4+<1892::aid-cncr2820400820>3.0.co;2-h

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  23 in total

1.  Second primary cancers after an index head and neck cancer: subsite-specific trends in the era of human papillomavirus-associated oropharyngeal cancer.

Authors:  Luc G T Morris; Andrew G Sikora; Snehal G Patel; Richard B Hayes; Ian Ganly
Journal:  J Clin Oncol       Date:  2010-12-28       Impact factor: 44.544

2.  Second primary cancer following adjuvant chemotherapy, radiotherapy and endocrine therapy for breast cancer: a nationwide survey on 47,005 Japanese patients who underwent mastectomy from 1963-1982.

Authors:  Z Iwasa; D Jinnai; H Koyama; N Sasano
Journal:  Jpn J Surg       Date:  1986-07

3.  Increased risk of second primary malignancy in pediatric and young adult patients treated with radioactive iodine for differentiated thyroid cancer.

Authors:  Jennifer L Marti; Kunal S Jain; Luc G T Morris
Journal:  Thyroid       Date:  2015-05-06       Impact factor: 6.568

4.  Incidence and Risk of Second Primary Malignant Neoplasm After a First Head and Neck Squamous Cell Carcinoma.

Authors:  Eric Adjei Boakye; Paula Buchanan; Leslie Hinyard; Nosayaba Osazuwa-Peters; Mario Schootman; Jay F Piccirillo
Journal:  JAMA Otolaryngol Head Neck Surg       Date:  2018-08-01       Impact factor: 6.223

5.  Clinical features of multiple primary carcinomas of the oral cavity.

Authors:  Ya-Dong Li; Xin Ma; Yao-Lun Han; Li-Wei Peng
Journal:  Exp Ther Med       Date:  2016-12-27       Impact factor: 2.447

6.  Incidence of bladder cancer after radiation for prostate cancer as a function of time and radiation modality.

Authors:  Aryeh Keehn; Ethan Ludmir; Jacob Taylor; Farhang Rabbani
Journal:  World J Urol       Date:  2016-09-14       Impact factor: 4.226

7.  Radiation-induced cancer after radiotherapy for non-Hodgkin's lymphoma of the head and neck: a retrospective study.

Authors:  Kazuma Toda; Hitoshi Shibuya; Keiji Hayashi; Fumio Ayukawa
Journal:  Radiat Oncol       Date:  2009-07-10       Impact factor: 3.481

8.  The effects of intravesical chemoimmunotherapy with epirubicin and bacillus Calmette-Guérin for prophylaxis of recurrence of superficial bladder cancer: a preliminary report.

Authors:  Y Uekado; A Hirano; T Shinka; T Ohkawa
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

9.  Increased risk of colorectal cancer following breast cancer.

Authors:  N Agarwal; M J Ulahannan; M A Mandile; C G Cayten; C S Pitchumoni
Journal:  Ann Surg       Date:  1986-03       Impact factor: 12.969

10.  Osteosarcoma and retinoblastoma: a shared chromosomal mechanism revealing recessive predisposition.

Authors:  M F Hansen; A Koufos; B L Gallie; R A Phillips; O Fodstad; A Brøgger; T Gedde-Dahl; W K Cavenee
Journal:  Proc Natl Acad Sci U S A       Date:  1985-09       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.